Treatment devised at Pitt could ease breathing woes
By Adam Smeltz
Published: Sunday, March 31, 2013, 12:59 p.m.
A new molecule developed in Pittsburgh eases inflammation in rodent cases of pneumonia, a discovery that could help people with respiratory infections, according to research released on Sunday.
A refined version of the treatment eventually “might be useful in improving outcomes” for pneumonia patients, said Dr. Rama Mallampalli, a vice chairman for research in the University of Pittsburgh School of Medicine. He said clinical trials for people could materialize within a few years.
The Department of Veterans Affairs and the National Institutes of Health supported the research, conducted during the past three to four years at Pitt and the VA Pittsburgh Healthcare System.
Mallampalli is the senior author in a paper about the findings, published this week in the journal Nature Immunology.
He said researchers are looking at whether other treatments could have a similar effect on ailments such as arthritis, asthma and colitis, all of which involve inflammation.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Century III new owner seeks to reverse vacancy trend with new theater
- Likely $2.3B influx puts PennDOT big-ticket road projects in play
- Hill District nonprofit’s finances are taking another dive
- Natural history museum in the red
- Pa. child abuse statutes faulted as too narrow
- American soldier charged in Iraq killings of deaf, unarmed teens
- Newsmaker: Jeffrey L. Brodsky
- Schmotzer says he got things done in Baldwin-Whitehall job